# **RESEARCH ARTICLES**

**Open Access** 

# Using weak signals to predict spontaneous breathing trial success: a machine learning approach

Romain Lombardi<sup>1,3\*</sup>, Mathieu Jozwiak<sup>2,3</sup>, Jean Dellamonica<sup>1,3</sup> and Claude Pasquier<sup>4</sup>

# Abstract

**Background** Weaning from mechanical ventilation (MV) is a key phase in the management of intensive care unit (ICU) patient. According to the WEAN SAFE study, weaning from MV initiation is defined as the first attempt to separate a patient from the ventilator and the success is the absence of reintubation (or death) within 7 days of extubation. Mortality rates increase with the difficulty of weaning, reaching 38% for the most challenging cases. Predicting the success of weaning is difficult, due to the complexity of factors involved. The many biosignals that are measured in patients during ventilation may be considered "weak signals", a concept rarely used in medicine. The aim of this research is to investigate the performance of machine learning (ML) models based on biosignals to predict spontaneous breathing trial success (SBT) using biosignals and to identify the most important variables.

**Methods** This retrospective study used data from two centers (Nice University Hospital, Archet and Pasteur) collected from 232 intensive care patients who underwent MV (149 successfully and 83 unsuccessfully) between January, 2020 and April, 2023. The study focuses on the development of ML algorithms to predict the success of the spontaneous breathing trial based on a combination of discrete variables and biosignals (time series) recorded during the 24 h prior to the SBT.

**Results** For the models tested, the best results were obtained with Support Vector Classifier model: AUC-PR 0.963 (0.936-0.970, p = 0.001), AUROC 0.922 (0.871-0.940, p < 0.001).

**Conclusions** We found that ML models are effective in predicting the success of SBT based on biosignals. Predicting weaning from mechanical ventilation thus appears to be a promising area for the application of AI, through the development of multidimensional models to analyze weak signals.

**Keywords** Mechanical ventilation, Weaning, Spontaneous breathing trial, Machine learning, Biosignal, Weak signals, ICU, Critical care

\*Correspondence: Romain Lombardi Iombardi.r@chu-nice.fr

Full list of author information is available at the end of the article



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, wisit http://creativecommons.org/licenses/by/4.0/.

#### Take Home Message

- The concept of "weak signals" is underused in medicine, because interpreting them is complex. The use of machine learning models to identify and interpret weak signals produces promising results
- Predicting the success of weaning is crucial for the management of patients on mechanical ventilation. This study suggests the application of multidimensional machine learning models to routinely collected biosignals could help predict spontaneous breathing trial success.

#### **Background and significance**

Endotracheal intubation is one of the most common resuscitation procedures and can be necessary for up to 90% of patients admitted to an intensive care unit (ICU), depending on the country [1]. This procedure has been shown to cause several complications, including: severe hypoxemia, severe arterial hypotension and hypoxic cardiac arrest [2, 3]. The weaning period is a key stage in the management of patients on mechanical ventilation (MV) and can take up half of the hospital stay. Weaning is defined as the first attempt to remove a patient from the ventilator, and success is the absence of reintubation or death within 7 days after extubation [4-6]. Spontaneous breathing trial (SBT) is commonly used to assess patient's readiness to be weaned. Up to 35% of patients subsequently experience extubation failure [7]. Regardless of the risks of reintubation, the mortality rate increases dramatically with the difficulty of weaning and reaching 38% in patients with most difficult weaning [8, 9]. Furthermore, the longer weaning is delayed, the higher is the length of hospital stays and the higher is the risk of failure [8]. Therefore, more reliable predictions of weaning success would not only assist clinicians and improve patient outcomes, but could also potentially have an economic impact by reducing hospital stays.

Artificial intelligence (AI) has already found several applications in various areas of medicine, particularly in the field of critical care, such as the management of fluid administration and vasopressors in patients with septic shock, prediction of sepsis or management of acute kidney injury [10–16]. However, data on the use of AI, and in particular machine learning (ML), in the MV weaning process are still scarce [14, 17, 18]. ML is a branch of AI characterized by models that learn based on data [19, 20]. The goal of ML is to discover recurring patterns in data sets, such as numbers, words or images in order to make predictions about new data [21]. ML algorithms can be divided into two categories, supervised and

unsupervised. Supervised algorithms, further divided into classification and regression algorithms, are based on learning with labeled data [20, 22]. Unsupervised algorithms, divided into clustering and dimensional reduction algorithms, do not require data labeling [22]. Several literature reviews have examined the potential impact of ML in everyday medical practice and in biology [23–25].

A key area in which ML may advance medical practice is in identifying and interpreting weak signals. Weak signals, first defined by Ansoff in the late twentieth century, are signals that appear to be incomplete, unstructured and unprocessed [26]. They are early, low-intensity pieces of information that indicate an emerging trend. If detected and interpreted accurately, they allow future events to be anticipated and thereby facilitate an appropriate response. In general, their sources and natures can vary from environmental to biological [27]. In the context of MV weaning, biological data, such as respiration and heart rate, may be weak signals that could be used to predict patient outcomes if processed appropriately. They are not widely used in this way because they are difficult to interpret, but they are interesting and original sources of data [28-32]. Few studies have used them to predict MV weaning outcomes [33, 34].

The aim of this research was to investigate the performance of ML models based on biosignals in predicting the success of SBT and identifying the most important variables.

#### Objectives

We aim to develop different ML models to predict SBT success or failure based on variables that were routinely collected during ICU patient care. Then, we assess the performance of the models and identify which variables are most important in predicting SBT success.

## Materials and methods

#### Data collection and study sample

This retrospective study used clinical, biological and biosignal data collected from patients who underwent MV in ICU at Nice University Hospitals l'Archet and Pasteur 2, tertiary teaching hospitals in the South of France, from January 2020 to April 2023. Data prior to January 2020 were excluded due to high levels of missing data. All the data (clinical, biological and biosignal) were obtained directly from electronic medical records and did not require any additional measurements. Patients prior to 2020 were excluded because the data quality was insufficient.

We screened all patients admitted to the ICU who underwent MV. Patients were included if they were over 18 years of age and underwent at least one SBT. The SBT could be performed in the following ways: T-piece test, or with a pressure support ventilation, with a positive end expiratory pressure (PEEP) of 4 (PEEP4) or with PEEP of 0 (ZEEP) [5, 35]. Patients were excluded if: no electronic report of the result was found, the patient was transferred to another department before the SBT was performed, the withdrawal test was not clearly explained in the medical record, or self-extubation or death occurred before the SBT. If more than one SBT was performed, only the first was considered in this study.

Finally, we included a total of 232 patients in this study.

This study was approved by the French Intensive Care Ethic Committee (CE 23-017) and was registered on ClinicalTrials.gov (NCT05886803).

#### Outcomes

The primary outcome of this study was the performance of different ML algorithms in predicting the success of the SBT. The criteria for SBT failure were agitation, altered mental status, respiratory rate >35/min, signs of respiratory distress, hemoglobin oxygen saturation measured by pulse oximetry <90%, or an increase of heart rate or blood pressure >20% from baseline at the end of SBT [36].

The secondary outcome was to determine which features were important in the algorithms' output.

#### Predictors

We included both discrete and continuous variables (biosignals). The discrete variables were: demographics (sex, age, inclusion center), comorbidities, severity scores at admission (Simplified Acute Physiology Score II or SAPSII, Apache2, Sepsis-related Organ Failure Assessment or SOFA), main reason for admission, main reason for intubation, body mass index (BMI) at time of SBT, weight gain since ICU admission, weaning test type (ZEEP, PEEP4, T-tube), non-invasive ventilation prior to intubation, ventilation characteristics (total number of days of invasive MV, time between intubation and first separation attempt, total number of days in volume-controlled ventilation (VCV) mode, total number of ventral decubitus, use of inhaled nitric oxide), use of drugs during SBT (purpose and dose), use of extra-renal replacement (type and duration), presence of ventilatorassociated pneumonia (VAP) before SBT and biology at the time of SBT. The continuous variables measured as time series were heart rate, systolic blood pressure, diastolic blood pressure, mean arterial blood pressure, cumulative and hourly urinary output, glycemia, clinical pulmonary infection score (CPIS), temperature, Richmond Agitation Sedation Scale (RASS) score, respiratory rate, SpO2 and ventilatory parameters (FiO2, PEEP, minute-volume and tidal volume). Most parameters were measured in intervals of one minute. We arbitrarily

chose to include data from 24 h prior to the SBT up until the start of the SBT. No additional measurements were required.

#### Data processing

We dealt with missing values through multiple imputation using the K-nearest neighbors (KNN) method [37, 38]. To overcome the problem of the unbalanced dataset the synthetic minority oversampling technique (SMOTE) was used (based on the generation of virtual individuals to increase the representation of the minority class) [39–41].

To input the time series data into the ML models, we used the feature extraction based on scalable hypothesis tests (FRESH) method. Given the large number of variables (and therefore dimensions) being considered, we applied two types of dimensional reduction to reduce the training time of the models. A variable is considered relevant if it is not independent of the target to be predicted (based on a statistical test appropriate for that variable and a p-value < 0.05). We then took all the relevant features with p-values < 0.05 and referred to this as the "light dimensional reduction". We tested another dimensional reduction, limiting the data to the first 20 relevant variables (smallest p-values, including both continuous and discrete variables), and refer to this as the "heavy dimensional reduction". See Supplementary Methods for more details.

A conceptual diagram of the data processing is shown in Fig. 1.

# Training of machine learning models and statistical analysis

We used several ML models: Logistic Regression (LR), Random Forest Classifier (RFC), Support Vector Classifier (SVC), K-nearest neighbors (KNN), Gradient Boosting Machine models (eXtremely Gradient Boosting or XGBoost and Light Gradient Boosted Machine or LGBM), and a stacking classifier (ensemble model, combining Random Forest Classifier and Support Vector Classifier). The hyperparameters were tuned using crossvalidation and grid search optimization. For training, we split the development cohort into 80% training and 20% test parts. A stratified split was also performed (maintaining the same success/failure ratio as in the overall dataset).

For the descriptive statistics of the population, continuous variables were expressed as median [interquartile range] or median ± standard deviation depending on the distribution, and categorical variables were expressed as number (percentage). We used a Shapiro–Wilk test to determine the normality of the continuous variables. We used either the  $\chi^2$  test or Fisher's exact test to compare



Fig. 1 Conceptual workflow of the data preprocessing. Time series are biosignals. The dotted arrow indicates a feedback loop. *FRESH* FeatuRe Extraction based on Scalable Hypothesis tests, *KNN* K-nearest neighbors, *SMOTE* synthetic minority oversampling technique, *SVC* Support Vector Classifier

categorical variables, and the Mann–Whitney U test to compare continuous variables. A p-value < 0.05 was considered to indicate a significant difference.

The following performance metrics were used to assess the ML models: area under the receiver

operating curve (AUROC), area under the precisionrecall curve (AUCPR), F1-score, sensitivity, specificity, positive predictive value (precision), negative predictive value and accuracy. We defined the minimum significance level for AUROC and AUCPR as 0.8. The confidence intervals were obtained with a bootstrap method (*n*-repetitions = 1000) and the AUCs were tested against random chance using a permutation method (*n*-repetitions = 1000).

The models were further explored using the Shapley additive explanations (SHAP) value, to determine the importance of different features (variables) in the model output [42].

To evaluate the influence of sample size, we tested the variation in AUROC and AUCPR values with different numbers of observations (25, 50, 75, 100, 125, 150, 175, 200 and total cohort).

#### **Development environment**

All the development work was conducted using Python version 3.9.16, along with the following libraries and their respective versions: NumPy 1.23.5, pandas 1.5.3, matplot-lib 3.7.1, seaborn 3.7.1, missingno 0.5.2, imblearn 0.10.1, joblib 1.1.1, tableone 0.7.12, TSfresh 0.20.0, Sklearn version 1.1.3, LightGBM 2.2.3, XGBoost 1.5.0, TensorFlow 2.12.0, SHAP 0.41.0.

#### Results

#### Patient characteristics

Overall, 232 patients were included in the development cohort used to assess the ML models: 149 patients (64.2%) succeeded in the SBT and 83 (35.8%) failed, and a further 71 patients were excluded due to a lack of data (55 without respiratory data and 16 without hemodynamic data); see Fig. 2.

There was no significant difference between the two groups in terms of severity at admission (SAPSII: 54.2 vs. 54.7, p = 0.843, SOFA score: 8.5 vs. 9, p = 0.675). Patients in the success group were younger (63 years vs. 66 years, p = 0.032) and were more likely to be admitted for neurological reasons (29.5% vs. 13.3%, *p*=0.008); see Table 1. Those who failed SBT tended to include a higher percentage of patients intubated mainly for respiratory reasons (74.7% vs. 54.4%, p = 0.004) and a lower percentage of neurological intubations (13.3% vs. 34.9%, p = 0.001). There were also more PEEP-ZEEP tests in the success group (62.4% vs. 42.2%, p = 0.003). There were more instances of VAP (71.1% vs. 19.5%, *p* < 0.001), longer hospital stays (13.9 days vs. 8.6 days, p < 0.001) and longer durations of volume-controlled ventilation (3 days vs. 2 days, p < 0.001) in the failure group compared with the success group. The delay from intubation to the first SBT was shorter for patients who passed their SBT (4 days vs. 6 days, p = 0.002). Patient characteristics and outcomes are summarized in Table 1.

#### Accuracy and predictive power of the models

The results of the AUROC curves and AUCPR obtained for the different algorithms after applying the different pre-processing methods (imputation, SMOTE and light dimensional reduction) are shown in Figs. 3 and 4 and Table 2. These results represent the performance of the ML models on the test dataset after training on the training dataset. In terms of AUROC, the best predictions were obtained with the SVC model: 0.922 (0.871–0.940, p < 0.001), and followed by the LGBM: 0.871 (0.812– 0.922, p < 0.001). The worst predictions were obtained with the Logistic Regression model with an AUROC of 0.77 (0.756–0.834, p < 0.001).

As shown in Fig. 4 and Table 2, the best AUCPR was also obtained by the SVC model: 0.963 (0.936–0.970, p=0.001). The combination of RFC and SVC model in the Stack Model produced worse results than the SVC model alone (AUCPR: 0.929, 95% CI 0.912–0.970, p=0.001).

The models performed worse when heavy dimensional reduction (20 features) was used; see Table 2. In this case, the KNN model obtained the highest AUCPR (KNN: 0.916, 95% CI 0.835–0.936, p=0.001) and AUROC (KNN: 0.849, 95% CI 0.733–0.886, p<0.001).

The calculation of SHAP values allowed us to determine the relative importance of different features in the models. In Supplementary Fig. 1, representing the 5 most important features, we can see that the presence of VAP before the SBT, fibrinogenemia at the time of SBT and weight gain since admission are decisive variables. The patients who failed the SBT were more likely to have VAP, and to have gained weight. The patients whose SBT was successful had lower fibrinogen levels than those the other group.

#### Effect of sample size

We evaluated the importance of sample size variation in the performance, in terms of AUROC and AUCPR; see Supplementary Figs. 2 and 3. There was an improvement in prediction for all the models up to 100 observations, except for Logistic Regression and KNN. After that, a plateau was reached where AUROCs essentially stagnated between 0.8 and 0.9, regardless of the increase in the number of observations. Support Vector Classifier predictions were the most stable; see Supplementary Fig. 2.

For the AUCPR values, the plateau was reached sooner, around 75 observations, see Supplementary Fig. 3. Similarly, for the AUROC values, SVC predictions were the most stable and Logistic Regression fluctuated the most.



Fig. 2 Study flowchart. SBT spontaneous breathing trial

# Table 1 Patient characteristics and outcomes

Characteristics of the patients at admission         Age, median [Q1,Q3], (years)         600 [95,74.0]         630 [52,07.20]         0033           Sex         Female, n (%)         32 (38.6)         59 (39.6)         0.987           Male, n (%)         10 (0.14)         50 (0.04)         0.847           SAPSI, mean (SD)         54.2 (18.6)         54.7 (18.1)         0.848           Apache2, median [Q1,Q3]         22.0 [16.0.28.5]         24.0 [18.0.30.0]         0.454           SOFA score, median [Q1,Q3]         25.8 [22.8.29.3]         26.4 [22.9.29.8]         0.358           MM, median [Q1,Q3]         25.8 [22.8.29.3]         26.4 (22.9.29.8]         0.358           Comotbiditis         11 (4.16.9)         30 (20.1)         0.60           Neurodespenerative disease, n (%)         7 (8.4)         14 (0.9)         0.07           Chronic kidney disease, n (%)         7 (8.4)         7 (4.7)         0.391           Arefal hypertension, n (%)         13 (15.7)         24 (16.1)         1.000           Diabeters mellitus, n (%)         20 (24.1)         34 (22.8)         0.020           Diabeters mellitus, n (%)         20 (24.1)         32 (20.1)         1.000           Diabeters mellitus, n (%)         20 (24.1)         32 (20.1)         1.000	Characteristics	SBT failure (n = 83)	SBT success (n = 149)	<i>p</i> -value
Age, median [Q1,Q3], (years)         660. [59,57.40]         630. [52,07.20]         0.033. [50,07]           Sec         Fermale, n (%)         51 (61,4)         90 (60,4)           SAPSLI, mean (SD)         54.2 (18.6)         54.7 (18.1)         0.633. [52,07.20]           SAPSLI, mean (SD)         54.2 (18.6)         54.7 (18.1)         0.634. [50,07.20]           SAPSLI, mean (SD)         54.2 (18.6)         54.7 (18.1)         0.634. [50,07.20]           SAPSLI, mean (SD)         55.6 (0,11.8)         90.6 (0,11.0)         0.644. [50,07.20]           SAPSLI, mean (SD)         55.6 (0,11.8)         90.6 (0,11.0)         0.644. [50,07.20]           Comorbidite         Immunosuppression, n (%)         14.1 (16.9)         30.2 (0,11.0)         0.664. [50,07.20]           Neurodegenerative disease, n (%)         7.8 (4,1         14.9 (4,0         0.993. [50,07.20]         0.007. [50,07.20]           Cohnoic kidney disease, n (%)         12.0 (4,0         12.0 (4,0)         0.007. [50,07.20]         0.007. [50,07.20]         0.007. [50,07.20]         0.007. [50,07.20]         0.007. [50,07.20]         0.007. [50,07.20]         0.007. [50,07.20]         0.007. [50,07.20]         0.007. [50,07.20]         0.007. [50,07.20]         0.007. [50,07.20]         0.007. [50,07.20]         0.007. [50,07.20]         0.007. [50,07.20]         0.007. [50,07.20]	Characteristics of the patients at admission			
Soc         99(39,6)         99(39,6)         0967           Female, n(%)         25 (61,6)         99(30,6)         0960,4)           SAPSIL, mean (SD)         54 (218,6)         54 7(18,1)         0843           Apache2, median [01,03]         220 (160,28,5]         40 (180,300)         0655           BMI, median [01,03]         258 [228,293]         264 (229,29,8]         0358           Comorbidities         1         14 (16,9)         02 (0,1)         0.666           Neurodegenerative disease, n (%)         7 (8,4)         14 (9,4)         0955           Chronic kidney disease, n (%)         7 (8,4)         14 (9,4)         0955           Chronic kidney disease, n (%)         7 (8,4)         7 (4,7)         0.37           Chronic kidney disease, n (%)         16 (2,9)         23 (15,4)         0.7           Chronic kidney disease, n (%)         7 (8,4)         7 (4,7)         0.393           Chronic kidney disease, n (%)         10 (2,9)         23 (15,4)         0.7           Chronic kidney disease, n (%)         10 (2,9)         23 (15,4)         0.7           Chronic kidney disease, n (%)         10 (2,9)         23 (15,4)         0.7           Chronic kidney disease, n (%)         10 (2,9)         33 (3,5,0)         0	Age, median [Q1,Q3], (years)	66.0 [59.5,74.0]	63.0 [52.0,72.0]	0.032
Female, n (%)         32 (38.6)         99 (39.6)         9987           Male, n (%)         16 (1.4)         90 (60.4)           SAPSI, men (SD)         42 (18.6)         4.7 (18.1)         0.843           Apache2, median [Q1,Q3]         22.0 [16.0,28.5]         24.0 [18.0,30.0]         0.454           SDAF accer, median [Q1,Q3]         25.8 [2.8,29.3]         0.6 (2.9,29.5)         0.358           SorA accer, median [Q1,Q3]         25.8 [2.8,29.3]         0.6 (2.0,11.0]         0.606           Neurodegenerative disease, n (%)         14 (16.9)         30 (20.1)         0.606           Neurodegenerative disease, n (%)         12 (14.5)         22 (14.8)         0.000           Chronic hepatic disease, n (%)         16 (9.2)         21 (14.5)         0.21 (14.7)         0.21 (17.2)           COPD, n (%)         10 (2.1)         30 (36.1)         53 (35.6)         1.000           Distructive sleep apnea, n (%)         7 (8.4)         7 (4.7)         0.301           Distructive sleep apnea, n (%)         13 (15.7)         24 (16.1)         0.000           Diabetes mellitur, n (%)         2 (0.2)         1.000         1.000           Diabetes mellitur, n (%)         2 (0.4)         1 (0.7)         0.000           Acteral hypertrophic acridopathy, n (%) <td>Sex</td> <td></td> <td></td> <td></td>	Sex			
Male, n (%)         51 (61.4)         90 (60.4)           SASIL, mean (SD)         52 (16.0.285)         24 01 (18.0.30.0)         0.454           Apache2, median [01,03]         250 (16.0.285)         24 01 (18.0.30.0)         0.454           SOFA score, median [01,03]         85 (50.11.8)         90 (60.1.0)         0.657           BM, median [01,03]         85 (80.11.8)         90 (60.1.0)         0.667           Comorbidities         rumunosuppression, n (%)         14 (16.9)         30 (20.1)         0.664           Neurodegenerative disease, n (%)         7 (8.4)         14 (9.4)         0.959           Chronic kidney disease, n (%)         19 (22.9)         23 (15.4)         0.217           Obthep kidney disease, n (%)         19 (22.9)         23 (15.4)         0.217           Obthep kidney disease, n (%)         10 (24.1)         3 (45.0)         0.100           Diabetes mellitus, n (%)         30 (36.1)         3 (35.0)         0.100           Diabetes mellitus, n (%)         13 (15.7)         24 (16.1)         1.000           Diabetes mellitus, n (%)         2 (24.1)         3 (20.0)         0.000           Obtrutive cardiopathy, n (%)         1 (16.3)         1 (16.3)         0.000           Obtrutive cardiopathy, n (%)         2 (24.3) <td>Female, n (%)</td> <td>32 (38.6)</td> <td>59 (39.6)</td> <td>0.987</td>	Female, n (%)	32 (38.6)	59 (39.6)	0.987
SAPSIL, mean (SD)         542 (18.6)         547 (18.1)         0.843           Apache2, median (Q1,Q3)         220 (160,28.5)         240 (180,30.0)         0.645           SDFA score, median (Q1,Q3)         258 [228,29.3]         264 (22.9.29.8]         0.558           Comorbidities                Immunosuppression, n (%)         14 (16.9)         30 (20.1)         0.664         0.664           Neurodegenerative disease, n (%)         7.8.4         14 (9.4)         0.955         0.606           Chronic hepatic disease, n (%)         7.8.4         7.4.7         0.917         0.664           Chronic kidney disease, n (%)         19 (22.9)         23 (15.4)         0.217         0.57           Obstructive sleep apnea, n (%)         7.8.4         7.4.7         0.931         0.56         0.007           Obstructive sleep apnea, n (%)         10 (2.9)         23 (15.4)         0.217         0.55         0.000         0.56         0.001         0.000         0.000         0.000         0.000         0.000         0.000         0.000         0.000         0.000         0.000         0.000         0.000         0.000         0.000         0.000         0.000         0.000         0.000	Male, n (%)	51 (61.4)	90 (60.4)	
Apache2, median [Q1,Q3]         220 [16,Q.8.5]         240 [18,Q.3.0.0]         0.454           SOFA score, median [Q1,Q3]         258 [22,22,23]         264 [22,22,28]         0.558           BMI, median [Q1,Q3]         258 [22,22,23]         264 [22,22,28]         0.588           Comorbidities         1         116.9         30 (20.1)         0.664           Neurodegenerative disease, n (%)         7 (8.4)         140 (49.4)         0.995           Chronic heidra disease, n (%)         22 (14.5)         22 (14.8)         1000           Chronic kidney disease, n (%)         7 (8.4)         7 (4.7)         0.391           Corronic kidney disease, n (%)         7 (8.4)         7 (4.7)         0.391           Corronic kidney disease, n (%)         7 (8.4)         7 (4.7)         0.391           Corronic kidney disease, n (%)         7 (8.4)         7 (4.7)         0.391           Obstructive sleep apnea, n (%)         7 (8.4)         7 (4.7)         0.393           Ibade cardiopathy, n (%)         10 (2.9)         32 (5.4)         0.000           Diade cardiopathy, n (%)         14 (2.8)         0.000         0.000           Arterial hypertension, n (%)         10 (0.4)         10 (0.7)         0.000           Arterial hypertension, n (%) <t< td=""><td>SAPSII, mean (SD)</td><td>54.2 (18.6)</td><td>54.7 (18.1)</td><td>0.843</td></t<>	SAPSII, mean (SD)	54.2 (18.6)	54.7 (18.1)	0.843
SOFA score, median [Q1,Q3]         8.5 [60,11.8]         9.0 [60,11.0]         0.675           BM, median [Q1,Q3]         25.8 [22,8,29.3]         26.4 [22,9,29.8]         0.358           Comorbidities	Apache2, median [Q1,Q3]	22.0 [16.0,28.5]	24.0 [18.0,30.0]	0.454
BMI, median [Q1,Q3]         258 [228,293]         26.4 [22.9,298]         0.358           Comorbidities	SOFA score, median [Q1,Q3]	8.5 [6.0,11.8]	9.0 [6.0,11.0]	0.675
Comorbidities         Immunosuppression, n (%)         14 (16.9)         30 (20.1)         0.664           Neurodegenerative disease, n (%)         7 (8.4)         14 (9.4)         0.995           Chronic hepatic disease, n (%)         12 (14.5)         22 (14.8)         10.000           Chronic kidney disease, n (%)         19 (22.9)         23 (15.4)         0.217           Obstructive sleep apnea, n (%)         7 (8.4)         7 (4.7)         0.391           Aterial hypertension, n (%)         30 (36.1)         53 (35.6)         1.0000           Diabetes mellitus, n (%)         20 (24.1)         34 (22.8)         0.953           Ischemic cardiopathy, n (%)         20 (24.1)         34 (22.8)         0.953           Unpertension, n (%)         13 (15.7)         24 (16.1)         1.0000           Diated cardiopathy, n (%)         2 (2.4)         3 (2.0)         1.0000           Obstructive cardiopathy, n (%)         1 (0.4)         1 (0.7)         1.0000           Atrial hip/lation, n (%)         8 (9.6)         19 (12.8)         0.620           Valuelopathy, n (%)         1 (0.4)         1 (0.7)         1.000           Main reason for ICU admission, n (%)         6 (55.4)         68 (45.6)         0.196           COVID19 admission, n (%)	BMI, median [Q1,Q3]	25.8 [22.8,29.3]	26.4 [22.9,29.8]	0.358
Immunosuppression, n %)         14 (16.9)         30 (20.1)         0.664           Neurodegenerative disease, n (%)         7 (8.4)         14 (9.4)         0.995           Chronic kidney disease, n (%)         12 (14.5)         22 (14.8)         10.00           COPD, n (%)         19 (22.9)         23 (15.4)         0.217           Obstructive sleep apnea, n (%)         30 (36.1)         53 (35.5)         10.00           Diabetes mellitus, n (%)         30 (36.1)         34 (22.8)         0.953           Schemic cardiopathy, n (%)         4 (4.8)         0.01         10.000           Diated cardiopathy, n (%)         2 (2.4)         3 (2.0)         10.000           Obstructive cardiopathy, n (%)         10 (0.7)         1.000         0.620           Valuopathy, n (%)         8 (9.6)         19 (12.8)         0.620           Valuopathy, n (%)         4 (4.8)         0.000         0.020           Valuopathy, n (%)         10.04         10.7)         1.000           Obstructive cardiopathy, n (%)         4 (2.4)         10.7)         0.000           Neuropathy, n (%)         4 (2.5)         0.000         0.000           Neuropathy and (%)         11 (13.3)         4 (2.95)         0.000           Surici and mi	Comorbidities			
Neurodegenerative disease, n (%)         7 (8.4)         14 (9.4)         0.995           Chronic hepatic disease, n (%)         12 (14.5)         22 (14.8)         0.007           Chronic kidney disease, n (%)         8 (9.6)         5 (3.4)         0.071           Obstructive sleep apnea, n (%)         7 (8.4)         7 (4.7)         0.391           Arterial hypertension, n (%)         30 (36.1)         53 (35.6)         1.000           Diabetes mellitus, n (%)         20 (24.1)         34 (22.8)         0.953           Sichemic ardiopathy, n (%)         13 (15.7)         24 (16.1)         0.000           Dilated cardiopathy, n (%)         2 (24.4)         3 (2.0)         1.000           Obstructive cardiopathy, n (%)         10 (0.4)         1 (0.7)         1.000           Atrial fibrillation, n (%)         8 (9.6)         19 (12.8)         0.620           Valvalopathy, n (%)         4 (7.7)         4 (2.7)         0.300           Main reason for ICU admission, n (%)         11 (13.3)         44 (2.9.5)         1.000           Neurologic admission, n (%)         11 (13.3)         44 (2.9.5)         1.000           Neurologic admission, n (%)         12 (14.5)         12 (8.1)         1.000           Surgical admission, n (%)         5 (6.0)	Immunosuppression, n (%)	14 (16.9)	30 (20.1)	0.664
Chronic kidney disease, n (%)         12 (14.5)         22 (14.8)         1.000           Chronic kidney disease, n (%)         8 (9.6)         5 (3.4)         0.071           COPD, n (%)         19 (22.9)         23 (15.4)         0.217           Obstructive sleep apnea, n (%)         30 (36.1)         53 (35.5)         1.000           Arterial hypertension, n (%)         20 (24.1)         34 (22.8)         0.953           Ischemic cardiopathy, n (%)         13 (15.7)         24 (16.1)         1.000           Dilated cardiopathy, n (%)         2 (24.1)         3 (2.0)         1.000           Obstructive actiopathy, n (%)         10(4)         1 (0.7)         1.000           Obstructive actiopathy, n (%)         8 (9.6)         19 (12.8)         0.620           Valuopathy, n (%)         4 (4.8)         0.000         0.000           Obstructive actiopathy, n (%)         4 (2.7)         0.300         0.000           Atrial fibrillation, n (%)         8 (9.6)         19 (12.8)         0.620           Valuopathy, n (%)         4 (2.7)         0.300         0.000           Neurologic admission, n (%)         24 (28.9)         44 (2.7)         0.300           Neurologic admission, n (%)         5 (6.0)         6 (4.0)         0.529	Neurodegenerative disease, n (%)	7 (8.4)	14 (9.4)	0.995
Chronic kidney disease, n (%)         8 (9.6)         5 (3.4)         0.071           COPD, n (%)         19 (22.9)         23 (15.4)         0.217           Obstructive sleep apne, n (%)         30 (3.61)         53 (35.6)         1.000           Thetrail hypertension, n (%)         20 (24.1)         34 (22.8)         0.953           Diabetes mellitus, n (%)         20 (24.1)         34 (22.8)         0.953           Diabete cardiopathy, n (%)         4 (4.8)         0.011           Hypertrophic cardiopathy, n (%)         2 (2.4)         3 (2.0)         1.000           Obstructive cardiopathy, n (%)         8 (9.6)         19 (12.8)         0.620           Obstructive cardiopathy, n (%)         8 (9.6)         19 (12.8)         0.620           Valvelopathy, n (%)         4 (1.7)         4 (2.7)         0.300           Main reason for ICU admission, n (%)         46 (55.4)         68 (45.6)         0.196           COVID 9 admission, n (%)         11 (13.3)         44 (29.5)         0.000           Neurologic admission, n (%)         12 (14.5)         12 (8.1)         0.000           Surgical admission, n (%)         12 (14.5)         12 (8.1)         0.000           Multivisceral failure admission, n (%)         12 (14.5)         12 (8.1)	Chronic hepatic disease, <i>n</i> (%)	12 (14.5)	22 (14.8)	1.000
COPD, n (%)         19 (22.9)         23 (15.4)         0.217           Obstructive sleep apnea, n (%)         7 (8.4)         7 (4.7)         0.391           Arterial hypertension, n (%)         30 (36.1)         53 (35.6)         1.000           Diabetes mellitus, n (%)         20 (24.1)         34 (22.8)         0.953           Sichemic cardiopathy, n (%)         13 (15.7)         24 (16.1)         1.000           Dilated cardiopathy, n (%)         4 (4.8)         0.010           Vippertrophic cardiopathy, n (%)         1 (0.4)         1 (0.7)         1.000           Atrial fibrillation, n (%)         8 (9.6)         19 (12.8)         0.620           Valvulopathy, n (%)         4 (6.5.4)         68 (45.6)         0.196           COVID 19 admission, n (%)         24 (28.9)         44 (29.5)         1.000           Nain reason for ICU admission, n (%)         6 (7.2)         1 (8.1)         1.000           Surgical admission, n (%)         1 (1.2)         1 (0.7)         1.000           Multrivisceral failure admission, n (%)         5 (6.0)         6 (4.0)         0.529           Shock admission, n (%)         1 (1.2)         1 (0.7)         0.000           Multrivisceral failure admission, n (%)         5 (6.0)         6 (4.0)         0.529	Chronic kidney disease, n (%)	8 (9.6)	5 (3.4)	0.071
Obstructive sleep apnea, n (%)         7 (8.4)         7 (4.7)         0.391           Arterial hypertension, n (%)         30 (36.1)         53 (35.6)         1.000           Diabetes mellitus, n (%)         20 (24.1)         34 (22.8)         0.933           Ischemic cardiopathy, n (%)         13 (15.7)         24 (16.1)         1.000           Diated cardiopathy, n (%)         4 (4.8)         0.010           Hypertrophic cardiopathy, n (%)         2 (24)         3 (2.0)         1.000           Obstructive cardiopathy, n (%)         10(0.4)         1 (0.7)         1.000           Obstructive cardiopathy, n (%)         4 (1.7)         4 (2.7)         0.300           Main reason for ICU admission*         8 (9.6)         19 (12.8)         0.620           COVID19 admission, n (%)         24 (28.9)         44 (2.9.5)         0.000           Neurologic admission, n (%)         24 (28.9)         44 (2.9.5)         0.000           Surgical admission, n (%)         11 (1.3)         44 (2.9.5)         0.000           Surgical admission, n (%)         16 (1.2)         10.07         1.000           Surgical admission, n (%)         16 (1.2)         12 (8.1)         0.000           Surgical admission, n (%)         16 (1.2)         12 (8.1)         0.00	COPD, n (%)	19 (22.9)	23 (15.4)	0.217
Arterial hypertension, n (%)         30 (36.1)         53 (35.6)         1.000           Diabetes mellitus, n (%)         20 (24.1)         34 (22.8)         0.953           Ischemic cardiopathy, n (%)         13 (15.7)         24 (16.1)         1.000           Diated cardiopathy, n (%)         4 (4.8)         0.010           Hypertrophic cardiopathy, n (%)         2 (2.4)         3 (2.0)         1.000           Obstructive cardiopathy, n (%)         10.04         10.07         1.000           Atrial fibrillation, n (%)         8 (9.6)         19 (12.8)         0.620           Valvulopathy, n (%)         4(1.7)         4 (2.7)         0.300           Main reason for ICU admission*           1.007         1.000           COVID 19 admission, n (%)         24 (2.8)         44 (2.9.5)         1.000           Neurologic admission, n (%)         11 (13.3)         44 (2.9.5)         0.000           Surgical admission, n (%)         12 (14.5)         1.007         1.000           Multivisceral failure admission, n (%)         12 (14.5)         1.000         0.529           Shock admission, n (%)         12 (14.5)         1.000         0.529           Shock admission, n (%)         12 (14.5)         1.000         0.529	Obstructive sleep apnea, <i>n</i> (%)	7 (8.4)	7 (4.7)	0.391
Diabetes mellitus, n (%)         20 (24.1)         34 (22.8)         0.9533           Ischemic cardiopathy, n (%)         13 (15.7)         24 (16.1)         1.000           Dilated cardiopathy, n (%)         4 (4.8)         0.014           Hypertrophic cardiopathy, n (%)         2 (2.4)         3 (2.0)         1.000           Obstructive cardiopathy, n (%)         10 (0.4)         1 (0.7)         1.000           Atrial fibrillation, n (%)         8 (9.6)         19 (12.8)         0.620           Valvulopathy, n (%)         4 (1.7)         4 (2.7)         0.300           Main reason for ICU admission*         Respiratory admission, n (%)         24 (28.9)         44 (29.5)         1.000           Neurologic admission, n (%)         11 (13.3)         44 (29.5)         0.000           Surgical admission, n (%)         5 (6.0)         6 (4.0)         0.529           Shock admission, n (%)         10 (1.2)         1 (0.7)         1.000           Multivisceral failure admission, n (%)         5 (6.0)         6 (4.0)         0.529           Shock admission, n (%)         10 (1.2)         1 (0.7)         0.000           Multivisceral failure admission, n (%)         6 (2.74.7)         81 (54.4)         0.004           Neurological, n (%)         6 (7.2)	Arterial hypertension, n (%)	30 (36.1)	53 (35.6)	1.000
Ischemic cardiopathy, n (%)         13 (15.7)         24 (16.1)         1.000           Dilated cardiopathy, n (%)         4 (4.8)         0.014           Hypertrophic cardiopathy, n (%)         2 (2.4)         3 (2.0)         1.000           Obstructive cardiopathy, n (%)         10.4)         1 (0.7)         1.000           Atrial fibrillation, n (%)         8 (9.6)         19 (12.8)         0.620           Valvulopathy, n (%)         41.7)         4 (2.7)         0.300           Main reason for ICU admission*         Respiratory admission, n (%)         46 (55.4)         68 (45.6)         0.196           COVID19 admission, n (%)         24 (28.9)         44 (29.5)         1.000           Neurologic admission, n (%)         11 (13.3)         44 (29.5)         0.000           Surgical admission, n (%)         6 (7.2)         12 (8.1)         1.000           Multivisceral failure admission, n (%)         5 (6.0)         6 (4.0)         0.529           Shock admission, n (%)         12 (14.5)         12 (8.1)         0.004           Main reason for intubation*         Respiratory, n (%)         62 (74.7)         81 (54.4)         0.004           Surgical, n (%)         5 (6.0)         4 (2.7)         0.288         Cardia carest, n (%)         0.004 <td>Diabetes mellitus, n (%)</td> <td>20 (24.1)</td> <td>34 (22.8)</td> <td>0.953</td>	Diabetes mellitus, n (%)	20 (24.1)	34 (22.8)	0.953
Dilated cardiopathy, n (%)         4 (4.8)         0.01 (c           Hypertrophic cardiopathy, n (%)         2 (2.4)         3 (2.0)         1.000           Obstructive cardiopathy, n (%)         1 (0.4)         1 (0.7)         1.000           Atrial fibrillation, n (%)         8 (9.6)         19 (12.8)         0.620           Valvulopathy, n (%)         4 (1.7)         4 (2.7)         0.300           Main reason for ICU admission*         8         6         5.4)         6.8 (45.6)         0.196           COVID19 admission, n (%)         24 (28.9)         44 (29.5)         1.000           Neurologic admission, n (%)         11 (13.3)         44 (29.5)         1.000           Surgical admission, n (%)         6 (7.2)         12 (8.1)         1.000           Surgical admission, n (%)         5 (6.0)         6 (4.0)         0.529           Shock admission, n (%)         10 (1.2)         10.7)         1.000           Multivisceral failure admission, n (%)         5 (6.0)         6 (4.0)         0.529           Shock admission, n (%)         10 (1.2)         10.7)         0.000           Multivisceral failure admission, n (%)         5 (6.0)         4 (2.7)         0.208           Cardiac Arrest demission, n (%)         5 (6.0)         4	lschemic cardiopathy, n (%)	13 (15.7)	24 (16.1)	1.000
Hypertrophic ardiopathy, n (%)         2 (2.4)         3 (2.0)         1.000           Obstructive cardiopathy, n (%)         1 (0.4)         1 (0.7)         1.000           Atrial fibrillation, n (%)         8 (9.6)         19 (12.8)         0.620           Valvulopathy, n (%)         4 (1.7)         4 (2.7)         0.300           Main reason for ICU admission*         Respiratory admission, n (%)         24 (28.9)         44 (29.5)         1.000           Neurologic admission, n (%)         11 (13.3)         44 (29.5)         0.000           Neurologic admission, n (%)         6 (7.2)         12 (8.1)         1.000           Surgical admission, n (%)         1 (1.2)         1 (0.7)         1.000           Multivisceral failure admission, n (%)         5 (6.0)         6 (4.0)         0.529           Shock admission, n (%)         12 (14.5)         12 (8.1)         0.000           Main reason for intubation*         E         E         Respiratory, n (%)         5 (6.0)         6 (4.0)         0.529           Main reason for intubation*         E         E         E         E         E         E           Respiratory, n (%)         5 (6.0)         4 (2.7)         0.288         Cardiac arrest, n (%)         5 (6.0)         4 (2.7)         0.	Dilated cardiopathy, n (%)	4 (4.8)		0.016
Obstructive cardiopathy, n (%)         10.4         10.7         1.000           Atrial fibrillation, n (%)         8 (9.6)         19 (12.8)         0.620           Valvulopathy, n (%)         4 (1.7)         4 (2.7)         0.300           Main reason for ICU admission*         8         68 (45.6)         0.196           COVID19 admission, n (%)         46 (55.4)         68 (45.6)         0.196           COVID19 admission, n (%)         24 (28.9)         44 (29.5)         1.000           Neurologic admission, n (%)         11 (13.3)         44 (29.5)         0.000           Cardiac Arrest admission, n (%)         6 (7.2)         12 (8.1)         1.000           Surgical admission, n (%)         1 (1.2)         1 (0.7)         1.000           Multivisceral failure admission, n (%)         5 (6.0)         6 (4.0)         0.529           Shock admission, n (%)         12 (14.5)         12 (8.1)         0.000           Main reason for intubation*         7         7         288           Respiratory, n (%)         5 (6.0)         6 (2.74.7)         81 (54.4)         0.000           Surgical, n (%)         5 (6.0)         4 (2.7)         0.288         Cardiac arrest, n (%)         5 (6.0)         4 (2.7)         0.288	Hypertrophic cardiopathy, n (%)	2 (2.4)	3 (2.0)	1.000
Atrial fibrillation, n (%)       8 (9.6)       19 (12.8)       0.620         Valvulopathy, n (%)       4(1.7)       4 (2.7)       0.300         Main reason for ICU admission*       8       8       45.6)       0.196         COVID19 admission, n (%)       46 (55.4)       68 (45.6)       0.196         Neurologic admission, n (%)       24 (28.9)       44 (29.5)       1.000         Neurologic admission, n (%)       11 (13.3)       44 (29.5)       0.006         Cardiac Arrest admission, n (%)       6 (7.2)       12 (8.1)       1.000         Surgical admission, n (%)       1 (1.2)       1 (0.7)       1.000         Multivisceral failure admission, n (%)       5 (6.0)       6 (4.0)       0.529         Shock admission, n (%)       12 (14.5)       12 (8.1)       0.196         Main reason for intubation*       8       8       9       0.007         Surgical, n (%)       62 (74.7)       81 (54.4)       0.004         Neurological, n (%)       5 (6.0)       4 (2.7)       0.288         Cardiac arrest, n (%)       5 (6.0)       4 (2.7)       0.288         Cardiac arrest, n (%)       6 (7.2)       13 (8.7)       0.882         Characteristics of the SBT       FEP-ZEEP, n (%)       35 (	Obstructive cardiopathy, n (%)	1(0.4)	1 (0.7)	1.000
Valvulopathy, n (%)       4 (1.7)       4 (2.7)       0.300         Main reason for ICU admission*	Atrial fibrillation. n (%)	8 (9,6)	19 (12.8)	0.620
Main reason for ICU admission*       88 (45.6)       0.196         COVID19 admission, n (%)       24 (28.9)       44 (29.5)       1.000         Neurologic admission, n (%)       11 (13.3)       44 (29.5)       0.004         Cardiac Arrest admission, n (%)       6 (7.2)       12 (8.1)       1.000         Surgical admission, n (%)       1 (1.2)       1 (0.7)       1.000         Multivisceral failure admission, n (%)       5 (6.0)       6 (4.0)       0.529         Shock admission, n (%)       12 (14.5)       12 (8.1)       0.196         Main reason for intubation*       8       8       5 (6.0)       6 (4.0)       0.529         Shock admission, n (%)       12 (14.5)       12 (8.1)       0.196         Main reason for intubation*       8       8       9       0.007         Surgical, n (%)       62 (74.7)       81 (54.4)       0.004         Neurological, n (%)       5 (6.0)       4 (2.7)       0.288         Cardiac arrest, n (%)       5 (6.0)       4 (2.7)       0.288         Cardiac arrest, n (%)       5 (6.0)       4 (2.7)       0.882         Characteristics of the SBT       9       93 (62.4)       0.002         With PEEP4, n (%)       33 (39.7)       49 (32.9)	Valvulopathy, n (%)	4(1.7)	4 (2.7)	0.300
Respiratory admission, n (%)         46 (55.4)         68 (45.6)         0.196           COVID19 admission, n (%)         24 (28.9)         44 (29.5)         1.000           Neurologic admission, n (%)         11 (13.3)         44 (29.5)         0.008           Cardiac Arrest admission, n (%)         6 (7.2)         12 (8.1)         1.000           Surgical admission, n (%)         1 (1.2)         1 (0.7)         1.000           Multivisceral failure admission, n (%)         5 (6.0)         6 (4.0)         0.529           Shock admission, n (%)         12 (14.5)         12 (8.1)         0.100           Main reason for intubation*         2         12 (14.5)         12 (8.1)         0.100           Neurological, n (%)         62 (74.7)         81 (54.4)         0.004           Neurological, n (%)         5 (6.0)         4 (2.7)         0.288           Cardiac arrest, n (%)         5 (6.0)         4 (2.7)         0.288           Cardiac arrest, n (%)         5 (6.0)         4 (2.7)         0.882           Characteristics of the SBT         2         93 (62.4)         0.002           With PEEP4, n (%)         33 (39.7)         49 (32.9)         0.365           T-tube, n (%)         15 (18.1)         7 (4.7)         0.002	Main reason for ICU admission*			
COVID19 admission, n (%)       24 (28.9)       44 (29.5)       1.000         Neurologic admission, n (%)       11 (13.3)       44 (29.5)       0.008         Cardiac Arrest admission, n (%)       6 (7.2)       12 (8.1)       1.000         Surgical admission, n (%)       1 (1.2)       1 (0.7)       1.000         Multivisceral failure admission, n (%)       5 (6.0)       6 (4.0)       0.529         Shock admission, n (%)       12 (14.5)       12 (8.1)       0.190         Main reason for intubation*       8 (54.4)       0.004         Respiratory, n (%)       62 (74.7)       81 (54.4)       0.004         Neurological, n (%)       11 (13.3)       52 (34.9)       0.007         Surgical, n (%)       5 (6.0)       4 (2.7)       0.288         Cardiac arrest, n (%)       5 (6.0)       4 (2.7)       0.288         Cardiac arrest, n (%)       5 (6.0)       4 (2.7)       0.288         Characteristics of the SBT       7       7       0.882         PEEP-ZEEP, n (%)       35 (42.2)       93 (62.4)       0.007         With PEEP4, n (%)       33 (39.7)       49 (32.9)       0.365         T-tube, n (%)       15 (18.1)       7 (4.7)       0.002	Respiratory admission, n (%)	46 (55.4)	68 (45.6)	0.196
Neurologic admission, n (%)         11 (13.3)         44 (29.5)         0.008           Cardiac Arrest admission, n (%)         6 (7.2)         12 (8.1)         1.000           Surgical admission, n (%)         1 (1.2)         1 (0.7)         1.000           Multivisceral failure admission, n (%)         5 (6.0)         6 (4.0)         0.529           Shock admission, n (%)         12 (14.5)         12 (8.1)         0.100           Main reason for intubation*         81 (54.4)         0.004           Neurological, n (%)         62 (74.7)         81 (54.4)         0.004           Neurological, n (%)         5 (6.0)         4 (2.7)         0.288           Cardiac arrest, n (%)         5 (6.0)         4 (2.7)         0.288           Cardiac arrest, n (%)         5 (6.0)         4 (2.7)         0.288           Characteristics of the SBT         5         6.00         4 (2.7)         0.288           PEEP-ZEEP, n (%)         35 (42.2)         93 (62.4)         0.007           With PEEP4, n (%)         33 (39.7)         49 (32.9)         0.365           T-tube, n (%)         15 (18.1)         7 (4.7)         0.002	COVID19 admission, n (%)	24 (28.9)	44 (29.5)	1.000
Cardiac Arrest admission, n (%)       6 (7.2)       12 (8.1)       1.000         Surgical admission, n (%)       1 (1.2)       1 (0.7)       1.000         Multivisceral failure admission, n (%)       5 (6.0)       6 (4.0)       0.529         Shock admission, n (%)       12 (14.5)       12 (8.1)       0.100         Multivisceral failure admission, n (%)       5 (6.0)       6 (4.0)       0.529         Shock admission, n (%)       12 (14.5)       12 (8.1)       0.100         Main reason for intubation*       62 (74.7)       81 (54.4)       0.004         Neurological, n (%)       62 (74.7)       81 (54.4)       0.004         Surgical, n (%)       5 (6.0)       4 (2.7)       0.288         Cardiac arrest, n (%)       6 (7.2)       13 (8.7)       0.882         Characteristics of the SBT       PEEP-ZEEP, n (%)       35 (42.2)       93 (62.4)       0.003         With PEEP4, n (%)       33 (39.7)       49 (32.9)       0.365         T-tube, n (%)       15 (18.1)       7 (4.7)       0.002	Neurologic admission. n (%)	11 (13.3)	44 (29.5)	0.008
Surgical admission, n (%)         1 (1.2)         1 (0.7)         1.000           Multivisceral failure admission, n (%)         5 (6.0)         6 (4.0)         0.529           Shock admission, n (%)         12 (14.5)         12 (8.1)         0.190           Main reason for intubation*         62 (74.7)         81 (54.4)         0.004           Neurological, n (%)         11 (13.3)         52 (34.9)         0.004           Surgical ac arrest, n (%)         5 (6.0)         4 (2.7)         0.288           Cardiac arrest, n (%)         5 (6.0)         4 (2.7)         0.882           Characteristics of the SBT         93 (62.4)         0.002           With PEEP4, n (%)         35 (42.2)         93 (62.4)         0.002           With PEEP4, n (%)         15 (18.1)         7 (4.7)         0.002	Cardiac Arrest admission, n (%)	6 (7.2)	12 (8.1)	1.000
Multivisceral failure admission, n (%)       5 (6.0)       6 (4.0)       0.529         Shock admission, n (%)       12 (14.5)       12 (8.1)       0.190         Main reason for intubation*       62 (74.7)       81 (54.4)       0.004         Neurological, n (%)       62 (74.7)       81 (54.4)       0.004         Surgical, n (%)       62 (74.7)       81 (54.4)       0.004         Characteristics of the SBT       52 (34.9)       0.001         PEEP-ZEEP, n (%)       5 (6.0)       4 (2.7)       0.882         Characteristics of the SBT       7       7       0.002         With PEEP4, n (%)       35 (42.2)       93 (62.4)       0.002         With PEEP4, n (%)       33 (39.7)       49 (32.9)       0.365         T-tube, n (%)       15 (18.1)       7 (4.7)       0.002	Surgical admission, n (%)	1 (1.2)	1 (0.7)	1.000
Shock admission, n (%)       12 (14.5)       12 (8.1)       0.190         Main reason for intubation*       62 (74.7)       81 (54.4)       0.004         Neurological, n (%)       62 (74.7)       81 (54.4)       0.004         Surgical, n (%)       11 (13.3)       52 (34.9)       0.001         Surgical, n (%)       5 (6.0)       4 (2.7)       0.288         Cardiac arrest, n (%)       6 (7.2)       13 (8.7)       0.882         Characteristics of the SBT       7       7       0.002         With PEEP4, n (%)       35 (42.2)       93 (62.4)       0.002         With PEEP4, n (%)       15 (18.1)       7 (4.7)       0.002	Multivisceral failure admission. $n$ (%)	5 (6.0)	6 (4.0)	0.529
Main reason for intubation*       62 (74.7)       81 (54.4)       0.004         Respiratory, n (%)       62 (74.7)       81 (54.4)       0.004         Neurological, n (%)       11 (13.3)       52 (34.9)       0.007         Surgical, n (%)       5 (6.0)       4 (2.7)       0.288         Cardiac arrest, n (%)       6 (7.2)       13 (8.7)       0.882         Characteristics of the SBT       7       7       0.002         With PEEP4, n (%)       35 (42.2)       93 (62.4)       0.002         With PEEP4, n (%)       15 (18.1)       7 (4.7)       0.002	Shock admission. n (%)	12 (14.5)	12 (8.1)	0.190
Respiratory, n (%)         62 (74.7)         81 (54.4)         0.004           Neurological, n (%)         11 (13.3)         52 (34.9)         0.007           Surgical, n (%)         5 (6.0)         4 (2.7)         0.288           Cardiac arrest, n (%)         6 (7.2)         13 (8.7)         0.882           Characteristics of the SBT         7         7         0.007           With PEEP4, n (%)         35 (42.2)         93 (62.4)         0.007           T-tube, n (%)         15 (18.1)         7 (4.7)         0.007	Main reason for intubation*			
Neurological, n (%)       11 (13.3)       52 (34.9)       0.001         Surgical, n (%)       5 (6.0)       4 (2.7)       0.288         Cardiac arrest, n (%)       6 (7.2)       13 (8.7)       0.882         Characteristics of the SBT       7       7       0.001         With PEEP4, n (%)       35 (42.2)       93 (62.4)       0.002         With PEEP4, n (%)       33 (39.7)       49 (32.9)       0.365         T-tube, n (%)       15 (18.1)       7 (4.7)       0.002	Respiratory, n (%)	62 (74.7)	81 (54.4)	0.004
Surgical, n (%)       5 (6.0)       4 (2.7)       0.288         Cardiac arrest, n (%)       6 (7.2)       13 (8.7)       0.882         Characteristics of the SBT       7       93 (62.4)       0.003         With PEEP4, n (%)       33 (39.7)       49 (32.9)       0.365         T-tube, n (%)       15 (18.1)       7 (4.7)       0.003	Neurological, n (%)	11 (13.3)	52 (34.9)	0.001
Cardiac arrest, n (%)       6 (7.2)       13 (8.7)       0.882         Characteristics of the SBT       7       7       93 (62.4)       0.002         With PEEP4, n (%)       35 (42.2)       93 (62.4)       0.365         T-tube, n (%)       15 (18.1)       7 (4.7)       0.002	Surgical, n (%)	5 (6.0)	4 (2.7)	0.288
Characteristics of the SBT       PEEP-ZEEP, n (%)       35 (42.2)       93 (62.4) <b>0.003</b> With PEEP4, n (%)       33 (39.7)       49 (32.9)       0.365         T-tube, n (%)       15 (18.1)       7 (4.7) <b>0.002</b>	Cardiac arrest, n (%)	6 (7.2)	13 (8.7)	0.882
PEEP-ZEEP, n (%)         35 (42.2)         93 (62.4)         0.003           With PEEP4, n (%)         33 (39.7)         49 (32.9)         0.365           T-tube, n (%)         15 (18.1)         7 (4.7)         0.002	Characteristics of the SBT			
With PEEP4, n (%)         33 (39.7)         49 (32.9)         0.365           T-tube, n (%)         15 (18.1)         7 (4.7) <b>0.002</b>	PEEP-7EEP. n (%)	35 (42.2)	93 (62.4)	0.003
T-tube, <i>n</i> (%) 15 (18.1) 7 (4.7) <b>0.002</b>	With PEEP4. n (%)	33 (39.7)	49 (32.9)	0.365
	T-tube, n (%)	15 (18.1)	7 (4.7)	0.002
Biology at the time of the SBT	Biology at the time of the SBT			
pH median [01 03] 75 [7475] 75 [7475] 0337	pH median [Q1 Q3]	75[7475]	7 5 [7 4 7 5]	0 337
PaCO2 median [Q1,Q3] mmHq 37 3 [34,041.8] 37 7 [34,641.0] 0.894	PaCO2 median [O1 O3] mmHq	37 3 [34 0 41 8]	377[346410]	0.894
PaO2 median [01 O3] mmHq 76 2 [68 3 87 0] 78 5 [71 5 89 4] 0 184	PaO2 median $[O1 O3]$ mmHq	76.2 [68.3.87.0]	78 5 [71 5 89 4]	0.184
Bicarbonate median [01 03] mmol/]     27 3 [25 0 30 2]     266 [23 5 29 3]     0.082	Bicarbonate median [01 03] mmol/l	27 3 [25 0 30 2]	266 [23 5 29 3]	0.087
Arterial lactate median [01 03] mmol/l     11 [0 7 1 4]     0 9 [0 7 1 4]     0 513	Arterial lactate median [01 03] mmol/l	1 1 [0 7 1 4]	09[0714]	0.513
Albumin median [01 03] o/l 23 5 [198 27 2] 25 1 [21 7 29 3] 0.04	Albumin median [01 03] a/l	23 5 [198 27 2]	25 1 [21 7 29 3]	0.047
Protide median [01 03] q/l 600 [56 5 64 0] 570 [54 0 62 0] 000	Protide median $[01 03] \alpha/l$	60.0 [56.5.64.0]	57.0 [54.0.62.0]	0.04

#### Table 1 (continued)

Characteristics	SBT failure (n = 83)	SBT success (n = 149)	<i>p</i> -value
Creatinine, median [Q1,Q3], µmol/l	72.0 [48.0,111.0]	67.0 [52.0,99.0]	0.880
Urea, median [Q1,Q3], mmol/l	10.5 [6.5,14.4]	8.7 [6.0,13.1]	0.180
Kaliemia, median [Q1,Q3], mmol/l	3.9 [3.6,4.1]	3.9 [3.5,4.1]	0.610
Natremia, median [Q1,Q3], mmol/l	140.0 [137.0,143.0]	140.0 [138.0,143.0]	0.529
Hemoglobin, median [Q1,Q3], g/dl	9.8 [8.7,11.6]	10.4 [8.8,12.0]	0.333
Hematocrit, median [Q1,Q3], I/I	0.3 [0.3,0.4]	0.3 [0.3,0.4]	0.383
Thrombocytes, median [Q1,Q3], ×10 <sup>9</sup> /l	259.0 [180.0,372.0]	226.0 [152.0,322.0]	0.024
CRP, median [Q1,Q3], mg/l	51.2 [17.9,108.4]	39.4 [8.0,102.2]	0.183
PCT, median [Q1,Q3], ng/ml	0.3 [0.2,1.1]	0.2 [0.1,1.8]	0.242
Fibrinogen, median [Q1,Q3], g/l	5.8 [4.0,7.1]	3.3 [2.5,5.2]	< 0.001
Leukocytes, median [Q1,Q3], ×10 <sup>9</sup> /I	11.8 [8.7,14.9]	11.6 [8.9,15.6]	0.917
Lymphocytes, median [Q1,Q3], ×10 <sup>9</sup> /l	1.1 [0.6,1.6]	1.2 [0.7,1.6]	0.435
Outcomes			
VAP, n (%)	59 (71.1)	29 (19.5)	< 0.001
LOS, median [Q1,Q3], day	13.9 [7.9,24.3]	8.6 [5.4,12.7]	< 0.001
Deceased status, n (%)	7 (8.4)	6 (4.0)	0.232
Extubation failure, n (%)	9 (10.8)	18 (12.1)	0.946
Total no. of days of invasive MV, median [Q1,Q3], day	10.1 [5.8,18.9]	4.8 [2.6,9.0]	< 0.001
Delay from intubation to first SBT, median [Q1,Q3], day	6.0 [3.0,13.0]	4.0 [2.0,7.0]	0.002
Total no. of days of VCV mode, median [Q1,Q3], day	3.0 [2.0,7.0]	2.0 [1.0,4.0]	< 0.001

BMI body mass index, COPD chronic obstructive pulmonary disease, CRP C-reactive protein, LOS length of stay, MV mechanical ventilation, PCT procalcitonin, PEEP positive end expiratory pressure, SAPS/I Simplified Acute Physiology Score, SBT spontaneous breathing trial, SOFA Sepsis-Related Organ Failure Assessment, VAP ventilator-associated pneumonia, VCV volume-controlled ventilation, ZEEP zero PEEP

Bold: p-value < 0.05

\* Because multiple reasons are possible the total number exceeds the number of patients

#### Discussion

This study investigated the application of ML algorithms to predict the outcomes (success and failure) of the SBT based on a wide variety of biosignals, and irrespective of the cause of intubation. Preprocessing methodologies enabled us to include all types of data in the computations. We found that patients who did not pass the SBT spent a longer time on MV (measured as time between intubation and the first test). It is well-established that delaying weaning significantly increases the risk of complications associated with MV, such as amyotrophy, VAP and delirium [8, 43]. An algorithm could be used to predict the success of the weaning test in real time. This study suggests it may be important to look for the presence of VAP and significant weight gain before carrying out the SBT, as well as examining biosignals recorded in the 24 h before the test, to assess its likely success. The use of variables derived from routinely collected data could therefore assist in the management of critically ill patients. It could potentially reduce the duration of invasive ventilation and associated complications, for example, if ML models can predict SBT success more reliably than current methods. Furthermore, such algorithms would make a significant medical and economic contribution by reducing the length of hospital stays. Further studies will be needed to investigate these possibilities.

It is an original study in terms of its methodology. A few authors have investigated the application of ML models to weaning from MV, but without advanced AI methodologies (no handling of unbalanced datasets, no data cleaning, etc.) [17, 18]. Without such methodology, the use of biosignals in MV weaning is not well-studied in the literature [33, 44].

The AUROC and AUCPR of the SVC model were superior to those of the other ML algorithms (including the ensemble model). The use of imputation with KNN, oversampling with SMOTE and light dimensional reduction of time series data by FRESH appear to be effective techniques for obtaining good predictions.

Our results show that key variables contributing to the model predictions are the presence of VAP before the SBT, fibrinogenemia at the time of SBT, weight gain since admission and the respiratory rate in the 24 h prior to the SBT. The importance of respiratory rate seems obvious, as a high respiratory rate prior to the weaning test will induce patient exhaustion and increase the risk of failure. By highlighting these



ROC curves for estimating

Fig. 3 ROC AUC curves used to assess the models. We used multiple imputation, light dimensional reduction (238 features) and SMOTE on the test dataset. The Stack model contains a combination of Support Vector and Random Forest Classifier. KNN K-nearest neighbors, LGBM light gradient boosting machine, SMOTE synthetic minority oversampling technique, SVC support vector classifier, XGBoost extreme gradient boosting

variables, we can influence the success of the weaning test. These are variables that are directly under the control of the clinician. For example, to achieve a favorable hydrosodic balance, it is possible to induce diuresis and reduce water intake. Preventing VAP, recognizing it early and treating it appropriately can have a direct effect on weaning success. It is also possible to act directly on respiratory rate, heart rate or blood pressure by initiating appropriate treatment, such as treating delirium, opioid withdrawal syndrome or hypertension for example.

Predicting the success of MV weaning using parameters that are routinely collected may enable better care. However, a prospective study with more data is needed.

#### Strengths

A strength of this study is the inclusion of patients from two centers (Archet Hospital and Pasteur Hospital, Nice), which makes the results more generalizable.

The inclusion of patients admitted to ICU for different etiologies is also a strength of this study. By including patients ventilated for respiratory, neurological or for cardiopulmonary arrest reasons, this algorithm can be applied to any patient admitted to an ICU and requiring MV.

In comparison with other research in the field of MV weaning, we found a similar success/failure rate in our development cohort [4, 8, 17]. To reduce the bias that can result from such an unbalanced dataset (e.g., biased



**Fig. 4** AUC precision-recall curves used to assess the models. We used multiple imputation, light dimensional reduction (238 features) and SMOTE on the test dataset. The Stack model contains a combination of Support Vector and Random Forest Classifier. *AUCPR* area under curve precision-recall, *KNN K*-nearest neighbors, *LGBM* light gradient boosting machine, *SMOTE* synthetic minority oversampling technique, *SVC* support vector classifier, *XGBoost* extreme gradient boosting

model and poor generalization), the SMOTE technique was used, which augments the minority class by creating artificial observations [39–41]. SMOTE has also proven effective in reducing overfitting (when the predicted model corresponds too closely to the training dataset and fails to generalize to new data) [45, 46].

We decided to use the AUCPR as the evaluation metric. The AUCPR is more suitable than AUROC for unbalanced data sets [47–49].

We have used simple variables that do not require additional measurements (such as blood tests, radiology, etc.) compared to what is done routinely. In fact, we have only integrated into our algorithms transformations of variables that were already available to us.

Trudzinski et al. note that determining the risk factors for weaning failure is complicated due to the number of studies and their heterogeneity. They conclude that multidimensional scores may be more useful in patient assessment [50]. Machine learning models provide a tool to analyze existing data in a systematic and consistent way and assist with its interpretation through multidimensional models.

The last and most important strength of this study is the rigorous framework development. Our data preprocessing using the imputation, FRESH and SMOTE techniques, enabled us to combine discrete variables and time series covering a broad range of patient characteristics. The resulting ML models predicted the success or failure of the SBT for patients with high accuracy. This methodology allowed us to obtain robust results that were superior to those of other studies looking at the use of ML in weaning, for example Lin et al. (AUROC: 0.908, 95% CI 0.864-0.943 for XGBOOST model) and Liu et al. (AUROC: 0.61, 95% CI 0.58–0.64 for Support Vector Machine model) [17, 18]. Compared to the recent study by Park et al., using ventilator data in a similar context with a multi-layer perceptron, our results are superior and more consistent (AUCPR 0.767, 95% CI 0.434-0.983) [34]. Our methodology allowed us to use weak signals (a signal that is difficult to "hear" and understand), signals that have not been widely used in medicine, because they are complex to use and understand [27, 51]. To avoid the phenomenon of the ML model learning from the

	F1-score	F1-score AUROC AUCPR			Sp	Se	PNV	PPV	
		<i>p</i> -value <i>p</i> -value							
Light dimensional reduct	tion (238 featur	es) + SMOTE							
Logistic Regression	0.828	0.77	< 0.001	0.852	0.012	0.765	0.8	0.684	0.857
95%CI		(0.756–0.834)		(0.821-0.904)					
Random Forest	0.82	0.806	< 0.001	0.887	0.001	0.647	0.833	0.688	0.806
95%CI		(0.747-0.9)		(0.84–0.945)					
XGBoost	0.836	0.855	< 0.001	0.904	0.004	0.882	0.767	0.682	0.920
95%CI		(0.804-0.912)		(0.871–0.960)					
LGBM	0.847	0.871	< 0.001	0.919	0.002	0.765	0.833	0.722	0.862
95%CI		(0.812–0.922)		(0.880–0.963)					
SVC	0.806	0.922	< 0.001	0.963	0.001	0.588	0.833	0.667	0.781
95%CI		(0.871–0.940)		(0.936–0.970)					
KNN	0.75	0.827	< 0.001	0.913	0.001	0.706	0.7	0.571	0.808
95%CI		(0.702–0.853)		(0.815–0.925)					
Stack model*	0.820	0.839	< 0.001	0.925	0.001	0.647	0.833	0.688	0.806
95%CI		(0.826–0.937)		(0.913–0.968)					
Heavy dimensional reduc	ction (20 feature	es) + SMOTE							
Logistic Regression	0.828	0.782	< 0.001	0.892	0.003	0.765	0.8	0.684	0.857
95%CI		(0.761–0.845)		(0.830-0.912)					
Random Forest	0.781	0.728	< 0.001	0.829	0.017	0.529	0.867	0.692	0.765
95%CI		(0.646–0.841)		(0.742–0.916)					
XGBoost	0.787	0.773	0.001	0.862	0.005	0.588	0.8	0.625	0.774
95%CI		(0.704–0.876)		(0.783–0.936)					
LGBM	0.767	0.714	0.007	0.813	0.022	0.588	0.767	0.588	0.767
95%CI		(0.641-0.812)		(0.716–0.897)					
SVC	0.844	0.796	< 0.001	0.868	0.007	0.588	0.9	0.769	0.794
95%CI		(0.678–0.849)		(0.720–0.923)					
KNN	0.807	0.849	< 0.001	0.916	0.001	0.765	0.767	0.65	0.852
95%CI		(0.733–0.886)		(0.835–0.936)					
Stack model*	0.852	0.825	< 0.001	0.885	0.003	0.706	0.867	0.750	0.839
95%CI		(0.706–0.857)		(0.790–0.930)					

#### Table 2 Results of the different machine learning models

We used light dimensional reduction (238 features) and heavy dimensional reduction (20 features) on the test dataset

AUCPR area under curve precision-recall, AUROC area under the receiver operating curve, KNN K-nearest neighbors, LGBM light gradient boosting machine, NBC Naïve Bayes Classifier, PNV predictive negative value, PPV predictive positive value, SMOTE synthetic minority oversampling technique, SVC support vector classifier, XGBoost extreme gradient boosting

Bold: indicates the highest value in each column

\* The Stack model is a combination of Support Vector and Random Forest Classifier

SBT, we excluded data recorded after the test began. In this way we limited overfitting on our dataset [52].

#### Limitations

The size of the patient sample included in this study is relatively small. This is due to the difficulty and time required to compile the various biosignals of interest for a sufficient number of patients. Patients admitted for very short stays with little or no respiratory failure (e.g., patients admitted for voluntary drug intoxication) did not require intubation or extensive monitoring. However, this sample size was sufficient to draw conclusions using ML models. A larger number (several thousand observations) would have been necessary to assess deep learning models. The number of patients was also consistent with the literature on similar study on different topics [24]. Furthermore, as shown in the supplementary analyses, beyond a hundred observations, the number of individuals appears to have little effect on the prediction accuracy.

The study was originally planned to use the data from around 500 patients. However, only 232 patients were included in the database. The main reason for this difference in sample size is that records prior to January 2020 had high levels of missing data. It was decided not to include records before this date to avoid impacting the training of the models and consequently the results obtained. To address the issue of the reduced sample size, an additional analysis was performed (see Supplementary Figs. 2 and 3) which showed that there was no significant improvement in results with an increased sample size beyond 100 patients.

The generation of a large number of explanatory variables can make the interpretation of the generated model difficult. This is why we opted to use the FRESH method to reduce the dimensionality of the temporal variables [53, 54].

The retrospective nature of the study can also be considered a limitation. However, this limitation is due to the design of the study, which specifically aimed at the development of the ML predictive algorithm. A second validation study will be performed using an external database to support the results of our analysis.

#### Future work

A future prospective, multicenter study is planned that will evaluate the application of the ML algorithm in real time. In addition, future work will focus on determining the optimal time period for measuring the biosignals prior to the SBT (e.g., 48 h, 12 h, 2 h) to obtain the most accurate predictions of success. The implementation of these models into internal electronic systems will be the final goal. Using variables derived from commonly collected data should make this easier. In fact, the models only use measures that are already available and do not require any additional invasive intervention. We can envision a future implementation in our electronic clinical system or ventilator system for example. In the long term, the use of an optimized algorithm could potentially decrease LOS and MV durations by identifying the optimal timing for weaning from MV.

### Conclusion

This original study, in terms of its methodology and research topic, showed an application of different ML models to predict SBT success for ICU patients, regardless of etiology. We demonstrated that the combined use of discrete variables (e.g., VAP, weight gain, etc.) and continuous variables (biosignals), along with data preprocessing techniques (imputation by KNN, dimensional reduction of the temporal variables by FRESH, and oversampling by SMOTE), produced better predictions than previous results in the literature. Furthermore, this work enabled us to use existing data and highlighted the potential usefulness of weak signals in intensive care. However, further studies on large external databases will be necessary to validate these results.

#### Abbreviations

Al	Artificial intelligence
AUCPR	Area under the precision-recall curve
AUROC	Area under the receiver operating curve
BMI	Body mass index
COPD	Chronic obstructive pulmonary disease
CPIS	Clinical Pulmonary Infection Score
CRP	C-reactive protein
FRESH	FeatuRe Extraction based on Scalable Hypothesis tests
ICU	Intensive care unit
KNN	K-nearest neighbors
LGBM	Light gradient boosted machine
LOS	Length of stay
LR	Logistic regression
ML	Machine learning
MV	Mechanical ventilation
PCT	Procalcitonin
PEEP	Positive end expiratory pressure
PNV	Predictive negative value
PPV	Predictive positive value
RASS	Richmond Agitation Sedation Scale
RFC	Random Forest Classifier
RR	Respiratory rate
SAPSII	Simplified Acute Physiology Score II
SBT	Spontaneous breathing trial
SHAP	SHapley Additive exPlanations
SMOTE	Synthetic minority oversampling technique
SOFA	Sepsis-Related Organ Failure Assessment
SVC	Support vector classifier
VAP	Ventilator-associated pneumonia
VCV	Volume controlled ventilation
XGBoost	EXtreme gradient boosting
<b>ZEED</b>	PEEP of zero

#### Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s40635-025-00724-0.

#### Supplementary Material 1.

Supplementary Material 2. Figure 1. The importance of different features in the models, expressed in SHAP values. We used light dimensional reduction. The highest SHAP values are at the top and the lowest at the bottom. Only the most important SHAP values are shown. The color code represents the feature value. The RR variables were features extracted from time series. RR: Respiratory Rate, c3: the c3 statistic measures non linearity in the time series, SHAP: SHapley Additive exPlanations, VAP: Ventilator-Associated Pneumonia.

Supplementary Material 3. Figure 2. Effect of varying sample size on AUROC for the different models in the test dataset. We used light dimensional reduction and the SMOTE technique. The total corresponds to N=232 observations. AUROC: Area Under the Receiver Operating Curve, KNN: K nearest neighbors, LGBM: Light Gradient Boosting Machine, SVC: Support Vector Classifier, XGBoost: Extreme Gradient Boosting.

Supplementary Material 4. Figure 3. Effect of varying sample size on AUCPR for the different models in the test dataset. We used light dimensional reduction and the SMOTE technique. The total corresponds to N=232 observations. AUCPR: Area Under Curve Precision-Recall, KNN: K nearest neighbors, LGBM: Light Gradient Boosting Machine, SVC: Support Vector Classifier, XGBoost: Extreme Gradient Boosting.

Acknowledgements Not applicable.

#### Author contributions

Conceptualization: RL, MJ, JD and CP; data curation: RL, MJ, JD and CP; formal analysis: RL, MJ, JD. and CP; investigation: RL and CP; methodology: RL, MJ and CP; project administration: RL, MJ, JD and CP; resources: RL, MJ, JD and CP; software: RL and CP; supervision: RL, MJ and CP; validation: RL, MJ, JD and CP; visualization: RL, MJ and CP; writing—original draft: RL; writing—review and editing: RL, MJ, JD and CP.

#### Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

#### Availability of data and materials

The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request.

#### Declarations

#### Ethics approval and consent to participate

This study was conducted according to the guidelines of the Declaration of Helsinki. This study was approved by the French Intensive Care ethics committee (CE 23-017). The trial was registered on ClinicalTrials.gov (NCT05886803).

#### **Consent for publication**

Not applicable.

#### **Competing interests**

The authors declare that they have no competing interests.

#### Author details

<sup>1</sup>Critical Care Unit, Pasteur 2 University Hospital, 30 Voie Romaine, 06000 Nice, France. <sup>2</sup>Critical Care Unit, Archet 1 University Hospital, 151 Rte de Saint-Antoine, 06200 Nice, France. <sup>3</sup>Université Côte d'Azur, UR2CA, Unité de Recherche Clinique Côte d'Azur, Nice, France. <sup>4</sup>I3S, CNRS, 2000 route des Lucioles, 06900 Sophia Antipolis, France.

Received: 25 July 2024 Accepted: 29 January 2025 Published online: 18 March 2025

#### References

- Simpson GD, Ross MJ, McKeown DW, Ray DC (2012) Tracheal intubation in the critically ill: a multi-centre national study of practice and complications. Br J Anaesth 108:792–799. https://doi.org/10.1093/bja/ aer504
- De Jong A, Rolle A, Molinari N et al (2018) Cardiac arrest and mortality related to intubation procedure in critically ill adult patients: a multicenter cohort study. Crit Care Med 46:532–539. https://doi.org/10.1097/ CCM.00000000002925
- Russotto V, Myatra SN, Laffey JG et al (2021) Intubation practices and adverse peri-intubation events in critically ill patients from 29 countries. JAMA 325:1164. https://doi.org/10.1001/jama.2021.1727
- Thille AW, Gacouin A, Coudroy R et al (2022) Spontaneous-breathing trials with pressure-support ventilation or a T-piece. N Engl J Med 387:1843– 1854. https://doi.org/10.1056/NEJMoa2209041
- Brochard L, Rauss A, Benito S et al (1994) Comparison of three methods of gradual withdrawal from ventilatory support during weaning from mechanical ventilation. Am J Respir Crit Care Med 150:896–903. https:// doi.org/10.1164/ajrccm.150.4.7921460
- Pham T, Heunks L, Bellani G et al (2023) Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study. Lancet Respir Med 11:465–476. https://doi.org/10.1016/S2213-2600(22)00449-0
- Thille AW, Boissier F, Muller M et al (2020) Role of ICU-acquired weakness on extubation outcome among patients at high risk of reintubation. Crit Care 24:86. https://doi.org/10.1186/s13054-020-2807-9

- Béduneau G, Pham T, Schortgen F et al (2017) Epidemiology of weaning outcome according to a new definition. The WIND study. Am J Respir Crit Care Med 195:772–783. https://doi.org/10.1164/rccm.201602-03200C
- Thille AW, Richard J-CM, Brochard L (2013) The decision to extubate in the intensive care unit. Am J Respir Crit Care Med 187:1294–1302. https://doi. org/10.1164/rccm.201208-1523Cl
- Komorowski M, Celi LA, Badawi O et al (2018) The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care. Nat Med 24:1716–1720. https://doi.org/10.1038/s41591-018-0213-5
- Celi L, Hinske LC, Alterovitz G, Szolovits P (2008) An artificial intelligence tool to predict fluid requirement in the intensive care unit: a proof-ofconcept study. Crit Care 12:R151. https://doi.org/10.1186/cc7140
- Cho K-J, Kim JS, Lee DH et al (2023) Prospective, multicenter validation of the deep learning-based cardiac arrest risk management system for predicting in-hospital cardiac arrest or unplanned intensive care unit transfer in patients admitted to general wards. Crit Care 27:346. https://doi.org/ 10.1186/s13054-023-04609-0
- Zubler F, Tzovara A (2023) Deep learning for EEG-based prognostication after cardiac arrest: from current research to future clinical applications. Front Neurol. https://doi.org/10.3389/fneur.2023.1183810
- 14. Fleuren LM, Dam TA, Tonutti M et al (2021) Predictors for extubation failure in COVID-19 patients using a machine learning approach. Crit Care 25:448. https://doi.org/10.1186/s13054-021-03864-3
- Nemati S, Holder A, Razmi F et al (2018) An interpretable machine learning model for accurate prediction of sepsis in the ICU. Crit Care Med 46:547–553. https://doi.org/10.1097/CCM.00000000002936
- Zhang Z, Ho KM, Hong Y (2019) Machine learning for the prediction of volume responsiveness in patients with oliguric acute kidney injury in critical care. Crit Care 23:112. https://doi.org/10.1186/s13054-019-2411-z
- Lin M-Y, Li C-C, Lin P-H et al (2021) Explainable machine learning to predict successful weaning among patients requiring prolonged mechanical ventilation: a retrospective cohort study in central Taiwan. Front Med 8:663739. https://doi.org/10.3389/fmed.2021.663739
- Liu W, Tao G, Zhang Y et al (2022) A simple weaning model based on interpretable machine learning algorithm for patients with sepsis: a research of MIMIC-IV and elCU databases. Front Med 8:814566. https:// doi.org/10.3389/fmed.2021.814566
- 19. Alpaydin E (2020) Introduction to machine learning, 4th edn. The MIT Press, Cambridge
- 20. Amanpreet S, Narina T, Aakanksha S. A review of supervised machine learning algorithms. IEEE
- Bishop CM (2016) Pattern recognition and machine learning, softcover reprint of the original 1st edition 2006 (corrected at 8th printing 2009). Springer, New York
- Alloghani M, Al-Jumeily D, Mustafina J et al (2020) A systematic review on supervised and unsupervised machine learning algorithms for data science. In: Berry MW, Mohamed A, Yap BW (eds) Supervised and unsupervised learning for data science. Springer International Publishing, Cham, pp 3–21
- Handelman GS, Kok HK, Chandra RV et al (2018) eDoctor: machine learning and the future of medicine. J Intern Med 284:603–619. https://doi. org/10.1111/joim.12822
- Triantafyllidis AK, Tsanas A (2019) Applications of machine learning in real-life digital health interventions: review of the literature. J Med Internet Res 21:e12286. https://doi.org/10.2196/12286
- Greener JG, Kandathil SM, Moffat L, Jones DT (2022) A guide to machine learning for biologists. Nat Rev Mol Cell Biol 23:40–55. https://doi.org/10. 1038/s41580-021-00407-0
- 26. Ansoff HI (1975) Managing strategic surprise by response to weak signals. Calif Manage Rev 18:21–33. https://doi.org/10.2307/41164635
- Mendonça S, Cardoso G, Caraça J (2012) The strategic strength of weak signal analysis. Futures 44:218–228. https://doi.org/10.1016/j.futures.2011. 10.004
- Dillen A, Steckelmacher D, Efthymiadis K et al (2022) Deep learning for biosignal control: insights from basic to real-time methods with recommendations. J Neural Eng 19:011003. https://doi.org/10.1088/1741-2552/ ac4f9a
- Da Silva HP, Fred A, Martins R (2014) Biosignals for everyone. IEEE Pervasive Comput 13:64–71. https://doi.org/10.1109/MPRV.2014.61
- Kaniusas E (2012) Fundamentals of biosignals. Biomedical signals and sensors I. Springer, Berlin, pp 1–26

- Lehman LH, Adams RP, Mayaud L et al (2015) A physiological time series dynamics-based approach to patient monitoring and outcome prediction. IEEE J Biomed Health Inform 19:1068–1076. https://doi.org/10.1109/ JBHI.2014.2330827
- Lehman L, Ghassemi M, Snoek J, Nemati S (2015) Patient prognosis from vital sign time series: combining convolutional neural networks with a dynamical systems approach. In: 2015 Computing in cardiology conference (CinC). IEEE, Nice, France. p. 1069–1072
- Park JE, Kim TY, Jung YJ et al (2021) Biosignal-based digital biomarkers for prediction of ventilator weaning success. IJERPH 18:9229. https://doi.org/ 10.3390/ijerph18179229
- 34. Park JE, Kim DY, Park JW et al (2023) Development of a machine learning model for predicting weaning outcomes based solely on continuous ventilator parameters during spontaneous breathing trials. Bioengineering 10:1163. https://doi.org/10.3390/bioengineering10101163
- Burns KEA, Rizvi L, Cook DJ et al (2021) Ventilator weaning and discontinuation practices for critically ill patients. JAMA 325:1173. https://doi. org/10.1001/jama.2021.2384
- Richard J, Beydon L, Cantagrel S, Cuvelier A, Fauroux B, Garo B, et al (2001) Sevrage de la ventilation mécanique (à l'exclusion du nouveau-né et du réveil d'anesthésie). Réanimation
- Kang H (2013) The prevention and handling of the missing data. Korean J Anesthesiol 64:402. https://doi.org/10.4097/kjae.2013.64.5.402
- Troyanskaya O, Cantor M, Sherlock G et al (2001) Missing value estimation methods for DNA microarrays. Bioinformatics 17:520–525. https://doi.org/ 10.1093/bioinformatics/17.6.520
- Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP (2002) SMOTE: Synthetic Minority Over-sampling Technique. JAIR 16:321–357. https://doi.org/10. 1613/jair.953
- Dablain D, Krawczyk B, Chawla NV (2022) DeepSMOTE: fusing deep learning and SMOTE for imbalanced data. IEEE Trans Neural Netw Learning Syst. https://doi.org/10.1109/TNNLS.2021.3136503
- Gök EC, Olgun MO (2021) SMOTE-NC and gradient boosting imputation based random forest classifier for predicting severity level of covid-19 patients with blood samples. Neural Comput Appl 33:15693–15707. https://doi.org/10.1007/s00521-021-06189-y
- 42. Zhang G, Shi Y, Yin P et al (2022) A machine learning model based on ultrasound image features to assess the risk of sentinel lymph node metastasis in breast cancer patients: applications of scikit-learn and SHAP. Front Oncol 12:944569. https://doi.org/10.3389/fonc.2022.944569
- Samadani A, Wang T, Van Zon K, Celi LA (2023) VAP risk index: early prediction and hospital phenotyping of ventilator-associated pneumonia using machine learning. Artif Intell Med 146:102715. https://doi.org/10. 1016/j.artmed.2023.102715
- Papaioannou V, Dragoumanis C, Pneumatikos I (2010) Biosignal analysis techniques for weaning outcome assessment. J Crit Care 25:39–46. https://doi.org/10.1016/j.jcrc.2009.04.006
- Cheng K, Zhang C, Yu H et al (2019) Grouped SMOTE with noise filtering mechanism for classifying imbalanced data. IEEE Access 7:170668– 170681. https://doi.org/10.1109/ACCESS.2019.2955086
- Liang XW, Jiang AP, Li T et al (2020) LR-SMOTE—an improved unbalanced data set oversampling based on K-means and SVM. Knowl-Based Syst 196:105845. https://doi.org/10.1016/j.knosys.2020.105845
- Ozenne B, Subtil F, Maucort-Boulch D (2015) The precision–recall curve overcame the optimism of the receiver operating characteristic curve in rare diseases. J Clin Epidemiol 68:855–859. https://doi.org/10.1016/j.jclin epi.2015.02.010
- Sofaer HR, Hoeting JA, Jarnevich CS (2019) The area under the precisionrecall curve as a performance metric for rare binary events. Methods Ecol Evol 10:565–577. https://doi.org/10.1111/2041-210X.13140
- Davis J, Goadrich M (2006) The relationship between Precision-Recall and ROC curves. In: Proceedings of the 23rd international conference on Machine learning—ICML'06. ACM Press, Pittsburgh, Pennsylvania, pp 233–240
- Trudzinski FC, Neetz B, Bornitz F et al (2022) Risk factors for prolonged mechanical ventilation and weaning failure: a systematic review. Respiration 101:959–969. https://doi.org/10.1159/000525604
- Ebadi A, Auger A, Gauthier Y (2022) Detecting emerging technologies and their evolution using deep learning and weak signal analysis. J Informet 16:101344. https://doi.org/10.1016/j.joi.2022.101344

- 52. Ying X (2019) An overview of overfitting and its solutions. J Phys: Conf Ser 1168:022022, https://doi.org/10.1088/1742-6596/1168/2/022022
- Christ M, Braun N, Neuffer J, Kempa-Liehr AW (2018) Time series FeatuRe extraction on basis of scalable hypothesis tests (tsfresh—a Python package). Neurocomputing 307:72–77. https://doi.org/10.1016/j.neucom. 2018.03.067
- Christ M, Kempa-Liehr AW, Feindt M (2016) Distributed and parallel time series feature extraction for industrial big data applications. https://doi. org/10.48550/ARXIV.1610.07717

#### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Romain Lombardi** is an intensivist specializing in pulmonology. He holds a Master of Science degree in Bioinformatics with a focus on Artificial Intelligence. RL combines his medical expertise with cutting-edge technology to advance the field of critical care, particularly in respiratory medicine. His interdisciplinary background enables him to leverage AI to enhance patient outcomes and contribute to innovative research in bioinformatics.